University of Ulm: Leukemia, Myeloid, Acute trials
The registry lists 19 Leukemia, Myeloid, Acute studies with University of Ulm as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 8Phase 3 9No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2RecruitingNCT04628026Phase 3
- Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-ProjectRecruitingNCT01252485
- Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse GeneticsActive, not recruitingNCT03897127Phase 3
- Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2CompletedNCT03338348Phase 2
- Study of Palbociclib in MLL-rearranged Acute LeukemiasStatus unknownNCT02310243Phase 1/2
- Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 MutationsTerminatedNCT02298166Phase 3
- Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedNCT02198482Phase 2
- Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)CompletedNCT02013648Phase 3
- Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)TerminatedNCT01770158
- Protocol in Acute Myeloid Leukemia With FLT3-ITDCompletedNCT01477606Phase 2
- Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 MutationCompletedNCT01237808Phase 3
- Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With AzacitidineCompletedNCT01180322Phase 2
- Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene MutationCompletedNCT00893399Phase 3
- Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)CompletedNCT00850382Phase 1/2
- Lenalidomide In Patients With Acute Myeloid LeukemiaTerminatedNCT00839059Phase 1
- All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00151255Phase 3
- Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00151242Phase 2/3
- Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic ResultCompletedNCT00146120Phase 3
- Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)CompletedNCT00143975Phase 2